HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies

Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials

(2012) Edith A. Perez et al.   MAYO CLINIC PROCEEDINGS

PTEN, PIK3CA, p-AKT, and p-p70S6K Status

(2010) Francisco J. Esteva et al.   AMERICAN JOURNAL OF PATHOLOGY

Hyperactivation of the PI3K-AKT Pathway Commonly Underlies Resistance to Trastuzumab in HER2 Amplified Breast Cancer.

(2010) S. Chandarlapaty et al.   CANCER RESEARCH

PI3 kinase activation and response to trastuzumab or lapatinib in HER-2 overexpressing locally advanced breast cancer (LABC).

(2010) I Migliaccio et al.   CANCER RESEARCH

Safety and Efficacy of Neratinib (HKI-272) in Combination with Paclitaxel in ErbB2+ Metastatic Breast Cancer.

(2010) L. Chow et al.   CANCER RESEARCH

Safety and Efficacy of Neratinib (HKI-272) in Combination with Vinorelbine in ErbB2+ Metastatic Breast Cancer.

(2010) A. Awada et al.   CANCER RESEARCH

Safety of Neratinib (HKI-272) in Combination with Capecitabine in Patients with Solid Tumors: A Phase 1/2 Study.

(2010) C. Saura et al.   CANCER RESEARCH

Pertuzumab and Trastuzumab: Re-Responses to 2 Biological Agents in Patients with HER2-Positive Breast Cancer Which Had Previously Progressed during Therapy with Each Agent Given Separately: A New Biological and Clinical Observation.

(2010) J. Baselga et al.   CANCER RESEARCH

Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor

(2010) M. Scaltriti et al.   CLINICAL CANCER RESEARCH

HER2and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial

(2010) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

(2010) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

(2010) Kimberly L. Blackwell et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy

(2010) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

(2010) Ian E. Krop et al.   JOURNAL OF CLINICAL ONCOLOGY

Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib

(2010) N. A. O'Brien et al.   MOLECULAR CANCER THERAPEUTICS

H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3

(2010) A Chakrabarty et al.   ONCOGENE

Resiliency and Vulnerability in the HER2-HER3 Tumorigenic Driver

(2010) D. N. Amin et al.   Science Translational Medicine

Protocol for PTEN Expression by Immunohistochemistry in Formalin-fixed Paraffin-embedded Human Breast Carcinoma

(2010) Rita A. Sakr et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens

(2009) K. L. Blackwell et al.   ANNALS OF ONCOLOGY

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

(2009) Teemu T. Junttila et al.   CANCER CELL

Elevation of Receptor Tyrosine Kinase EphA2 Mediates Resistance to Trastuzumab Therapy

(2009) G. Zhuang et al.   CANCER RESEARCH

Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models

(2009) W. Scheuer et al.   CANCER RESEARCH

Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL

(2009) L. Liu et al.   CANCER RESEARCH

PIK3CA Mutation Associates with Improved Outcome in Breast Cancer

(2009) K. Kalinsky et al.   CLINICAL CANCER RESEARCH

A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

(2009) K.-K. Wong et al.   CLINICAL CANCER RESEARCH

Resistance to Trastuzumab in Breast Cancer

(2009) P. R. Pohlmann et al.   CLINICAL CANCER RESEARCH

Blood-Brain Barrier Disruption and Intra-Arterial Methotrexate-Based Therapy for Newly Diagnosed Primary CNS Lymphoma: A Multi-Institutional Experience

(2009) Lilyana Angelov et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

(2009) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth

(2009) S Chandarlapaty et al.   ONCOGENE

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer

(2008) H. J. Burstein et al.   ANNALS OF ONCOLOGY

A Central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy

(2008) S. T. Lee-Hoeflich et al.   CANCER RESEARCH

An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

(2008) K. Stemke-Hale et al.   CANCER RESEARCH

Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells

(2008) D. L. Shattuck et al.   CANCER RESEARCH

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate

(2008) G. D. Lewis Phillips et al.   CANCER RESEARCH

Can We Circumvent Resistance To ErbB2-Targeted Agents By Targeting Novel Pathways?

(2008) Mark Pegram   Clinical Breast Cancer

SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase Dependent Cancers

(2008) S. Chandarlapaty et al.   CLINICAL CANCER RESEARCH

Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer

(2008) C. C. Portera et al.   CLINICAL CANCER RESEARCH

Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer

(2008) Anna Maria Storniolo et al.   JOURNAL OF CLINICAL ONCOLOGY

Including Persons With HIV Infection in Cancer Clinical Trials

(2008) Govind C. Persad et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Predictive Biomarker Profiles for Response Targeting Human Epidermal Growth Factor Receptor 2 (HER-2) in Advanced Inflammatory Breast Cancer With Lapatinib Monotherapy

(2008) Stephen Johnston et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer

(2008) Henry L. Gomez et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

(2008) Andrew D. Seidman et al.   JOURNAL OF CLINICAL ONCOLOGY

HER2Status and Benefit from Adjuvant Trastuzumab in Breast Cancer

(2008) Soonmyung Paik et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

(2008) M Scaltriti et al.   ONCOGENE

Development and application of Hsp90 inhibitors

(2007) D SOLIT   DRUG DISCOVERY TODAY